Isavuconazole: Real-World Data and Clinical Considerations for Pediatric Patients
Pediatric Drugs · 2026-11 · 28 (6) · 637-655
DOI: 10.1007/s40272-026-00780-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pediatric Drugs, online erschienen am 16.10.2026. Verfasst von Lorenzo Chiusaroli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Infectious Diseases, Department of Women's and Children's Health, University of Padua, Padua, Italy. Hauptthemen laut MEDLINE: Antifungal Agents, Triazoles, Nitriles, Pyridines. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Universitätsklinikum Münster.
Abstract (Originalsprache)
Isavuconazole (ISAV) is a broad-spectrum triazole antifungal approved for the treatment of invasive aspergillosis and mucormycosis and has recently received approval for use in children ≥1 year of age. Pediatric approval was based on limited registration data, underscoring the importance of real-world evidence to better define efficacy and safety in children and adolescents. In this manuscript, we reviewed pediatric registration trials and real-world studies evaluating ISAV, with a focus on treatment and prophylaxis indications, pharmacokinetics, and safety. The literature review was conducted using PubMed, Embase, and Cochrane databases to identify relevant real-world and clinical studies published between January 1, 2005, and October 31, 2025. Studies reporting ISAV use in patients
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Infectious Diseases, Department of Women's and Children's Health, University of Padua, Padua, Italy.
- Faculty of Medicine, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University Hospital Cologne, University of Cologne, Cologne, Germany.
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
- Department I of Internal Medicine, Excellence Center for Medical Mycology, University of Cologne, Cologne, Germany.
- Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology, University Children's Hospital Münster, Münster, Germany.
- Department of Pediatric Respiratory Medicine, Immunology and Critical Care, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Healt…
Förderung
- Universitätsklinikum Münster
Zitieren
APA
Chiusaroli, L., Seidel, D., Ebrahimi-Fakhari, D., Martin, L., Ehlert, K., Groll, A. H., & Pana, Z. D. (2026). Isavuconazole: Real-World Data and Clinical Considerations for Pediatric Patients. Pediatric Drugs, 28(6), 637-655. https://doi.org/10.1007/s40272-026-00780-3
Vancouver
Chiusaroli L, Seidel D, Ebrahimi-Fakhari D, Martin L, Ehlert K, Groll AH, et al. Isavuconazole: Real-World Data and Clinical Considerations for Pediatric Patients. Pediatric Drugs. 2026;28(6):637-655. doi:10.1007/s40272-026-00780-3
BibTeX
@article{Chiusaroli2026,
author = {Chiusaroli, Lorenzo and Seidel, Danila and Ebrahimi-Fakhari, Daniel and Martin, Luise and Ehlert, Karoline and Groll, Andreas H and Pana, Zoi Dorothea},
title = {Isavuconazole: Real-World Data and Clinical Considerations for Pediatric Patients},
journal = {Pediatric Drugs},
year = {2026},
volume = {28},
number = {6},
pages = {637--655},
doi = {10.1007/s40272-026-00780-3}
}
EUVIMED